Back to Search
Start Over
Novel Antifungals for the Treatment of Vulvovaginal Candidiasis: Where Are We?
- Source :
-
touchREVIEWS in Infectious Diseases . 2022, Vol. 1 Issue 1, p16-25. 10p. - Publication Year :
- 2022
-
Abstract
- Vulvovaginal candidiasis (VVC) is a common health-related issue and the second most common cause of vaginitis. Previously, azole antifungals were the mainstay of VVC treatment. Additionally, boric acid and nystatin have been used topically for management of VVC. Despite being effective and well tolerated by most patients, the use of azoles may be limited in some cases. Currently, two new antifungal agents have received US Food and Drug Administration approval for use in the management of VVC. In this article, we briefly review treatment regimens used for the management of VVC over the past decade, the newly approved agents and their possible clinical application, and future treatment considerations. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 2755113X
- Volume :
- 1
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- touchREVIEWS in Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 161505124
- Full Text :
- https://doi.org/10.17925/ID.2022.1.1.16